CNX Therapeutics wins CSR Programme of the Year at 2025 Pharma Industry Awards

London, England [Thursday 11 September] – CNX Therapeutics, a specialty pharmaceutical company, has won CSR Programme of the Year at the 2025 Pharma Industry Awards for its submission entitled ‘Talent without barriers: CNX’s partnership to transform pharma industry recruitment’. This approach saw CNX partner with the Social Mobility Foundation to bring five exceptional interns into key business areas of the company. The interns joined CNX’s Quality, Legal, Commercial, Data and People & Sustainability teams.

The programme provided 12-month placements for interns from underrepresented backgrounds, using a values-based recruitment approach that focuses on potential rather than privilege.

"This award belongs to everyone who made this programme a success – the exceptional interns who embraced every opportunity, our People team who designed and supported it, and the entire CNX team who welcomed them with open arms,” said Jenny Chapman, Chief People Officer at CNX Therapeutics. “It perfectly sums up what CNX is about - an organisation that's more than the sum of its parts."

Jessica Dall, Learning, Development & Sustainability Manager at CNX Therapeutics said: “Working with our interns and supporting their development has been one of the most rewarding aspects of my role. Seeing our former intern Akua secure her career aspiration in being able to start the CIPD qualification shows exactly what we hoped to achieve - launching meaningful careers and opening doors that might otherwise have remained closed."

'We're proud to create opportunities alongside CNX Therapeutics”, said Eloise Baker, Relationship Manager at SMF. “This award highlights our partnership's impact and our shared commitment to ensuring young people from all backgrounds can thrive”.

Khadijah Chowdhury, Legal Intern at CNX Therapeutics, said: "Working at CNX has been such a positive experience - I've learned practical skills, gained confidence and discovered what I'm capable of. It's given me a real foundation for whatever comes next.”

CNX Therapeutics was also a finalist in the Pharma Company of the Year category, alongside industry giants AstraZeneca and Ipsen.

The CSR Programme of the Year win marks CNX's second major industry award since its founding, following CEO Guy Clark’s recognition as CEO of the Year at CPHI 2024. The consecutive awards reflect CNX's strong performance and people-focused approach.